Trial intelligence / Profile preview

Phase II study of pyrotinib maleate in HER2-mutant advanced lung adenocarcinoma

CTR20160434Phase 2Completed

Sponsor

Hengrui Therapeutics

Start

Oct 2016

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1